TrialBreast cancer research and treatment2018

Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy.

B Pistilli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.